#Hong Kong #share repurchase #Sisram Medical #Energy-Based Devices

Sisram Medical Unveils Strategic Share Repurchase Plan

Sisram Medical Ltd, listed under the ticker 1696.HK, has made a significant announcement regarding its future financial strategy. The company, a recognized global leader in the wellness industry focusing on Energy-Based Devices (EBD) and injectables, has unveiled a share repurchase plan. This initiative is aimed at acquiring up to 1% of its total issued shares from the open market, subject to certain market conditions.

By maintaining a robust share repurchase policy, Sisram demonstrates confidence in its long-term business fundamentals and reinforces its commitment to enhancing shareholder value. The repurchased shares can either be cancelled or retained as treasury shares depending on the company's future capital management strategies. This flexibility highlights Sisram's cautious approach to financial risk management while aiming for sustainable growth.

In the first half of 2026, Sisram Medical achieved promising results, with revenues increasing to US$171.4 million, reflecting a 3.6% rise year-over-year (YoY). Particularly noteworthy was the performance in international markets, which experienced a 16.7% growth compared to the previous year, culminating in US$127 million in revenue. The Asia-Pacific (APAC) region notably excelled, contributing US$78.4 million and growing by 19.1% YoY, showcasing the region's strength as a key driver of Sisram's international business.

The injectables segment has also registered impressive growth, with a remarkable 54.2% increase in revenue, totaling US$22.2 million, which now constitutes 12.9% of the company's overall revenue. This solid performance in injectables indicates the sector’s critical role as a second growth engine for Sisram, alongside its established EBD businesses.

In terms of operational momentum, Sisram's flagship products in EBD, such as the Alma Harmony and Hybrid systems, continue to gain traction, further confirmed by successful new product launches throughout APAC and localization efforts within the Chinese market. Moreover, the gradual commercialization of DAXXIFY in mainland China and the expansion of other products like Profhilo and Hallura contribute to the diversification of the company's portfolio and growth strategy.

Looking forward, Sisram Medical plans to deepen the strategic integration of research and development (R&D) with global commercial operations, anchored in its three strategic hubs in Israel, the United States, and China. These initiatives aim to drive the evolution of core products, translate innovations into tangible commercial success, and expedite the clearance and marketing of key products within critical global markets. To further complement these plans, Sisram is also eager to explore partnerships and strategic opportunities that will enhance synergies across its wellness ecosystem.

Citing the company’s unwavering dedication to shareholder value creation, Jiahong Li, Co-CEO and CFO of Sisram, emphasized, "This share repurchase reflects the outcomes of our extensive evaluation of the company’s performance and market conditions. By prioritizing robust financial health and operational efficiency, we remain confident that Sisram will achieve recognized long-term value in the marketplace. We look ahead to executing our strategic goals effectively while delivering sustainable value to our shareholders."

Established over 25 years ago, Sisram Medical Ltd has built a legacy of innovation rooted in clinical excellence within the aesthetic medical solutions sector. With a presence in more than 110 countries and regions, Sisram continuously strives to set industry standards concerning safety, efficacy, and personalized aesthetic care for millions.

In summary, Sisram Medical's proactive approach to share repurchase not only reinforces shareholder confidence but also underscores its dedication to long-term growth strategies in the ever-evolving landscape of medical aesthetics.